Friday, May 24, 2013 | 8:30 AM - 4:30 PM
Speakers: Scott A. Armstrong (Memorial Sloan-Kettering Cancer Center), Stephen Baylin (The Johns Hopkins University School of Medicine), Robert A. Copeland (Epizyme, Inc.), Vicki L. Goodman (GlaxoSmithKline), Haitao Li (Tsinghua University, China), X. Shirley Liu (Dana-Farber Cancer Institute), Robert Sims (Constellation Pharmaceuticals, Inc.), Alexander Tarakhovsky (The Rockefeller University)
Epigenetic research has shown that heritable changes in cancer cell transformation occur beyond the primary DNA sequence. This symposium reviews epigenetic regulators in cancer development and progress in designing therapies targeting the epigenome.
Thursday, May 30, 2013 | 9:00 AM - 5:00 PM
Review progress on key aspects of the Plasmodium vivax research agenda as they pertain to malaria treatment, control, and elimination through a series of free, interdisciplinary workshops.
Thursday, June 6, 2013 | 8:30 AM - 6:30 PM
Organizers: Sharon Akabas (Columbia University), Gerald Friedman (The Mount Sinai Hospital), Martin Kohlmeier (University of North Carolina), Charlotte Pratt (National Institute of Health), Gwen Twillman (American Society for Nutrition), Mandana Arabi (The Sackler Institute for Nutrition Science), Brooke Grindlinger (The New York Academy of Sciences)
This conference aims to revisit the current nutrition curricula for health professionals and to explore how trainings can better provide the skills necessary for implementing the array of preventative and therapeutic nutrition interventions available. Presented as part of the Translational Medicine Initiative.
June 11 - 13, 2013
Organizers: Mark E. Davis (California Institute of Technology, Pasadena), Omid Farokhzad (Brigham and Women's Hospital, Harvard Medical School), Brooke Grindlinger (The New York Academy of Sciences), Melanie Brickman Stynes (The New York Academy of Sciences), Roger Kornberg (Stanford University School of Medicine), Robert S. Langer (Massachusetts Institute of Technology), Konstantin Severinov (Rutgers the State University of New Jersey)
Throughout the past decade nanoparticles, and specifically nanoparticle drug delivery systems, have emerged at the forefront of cancer therapies. This conference will discuss: nanodiagnostics for cancer biomarkers and imaging, toxicity and safety; nanovaccines and nanoimmunotherapeutics; targeted delivery in tumors; and nanoparticle-based gene therapy.
Wednesday, June 12, 2013 | 7:45 AM - 6:00 PM
In-house event is SOLD OUT! Register for the live webinar.
Speakers: Martin J. Blaser (New York University School of Medicine), Sir Harry Burns (Scottish Government, Scotland), Patrice D. Cani (Université Catholique de Louvain, Belgium), Fred H. Degnan (King & Spalding LLP), Joël Doré (Institut National de la Recherche Agronomique, France), Jane A. Foster (McMaster University, Canada), Gary Frost (Imperial College London, United Kingdom), Patricia L. Hibberd (Harvard Medical School / Massachusetts General Hospital for Children), John Hutton (University of York, United Kingdom), Todd Klaenhammer (North Carolina State University), David A. Mills (University of California, Davis), Max Nieuwdorp (University of Amsterdam, The Netherlands), Bruno Pot (Institut Pasteur de Lille, France), Rowena Pullan (Pfizer Consumer Healthcare), Helen E. Raybould (University of California, Davis), Gregor Reid (Western University / Lawson Health Research Institute, Canada), David A. Relman (Stanford University School of Medicine), Andrew Serazin (Matatu LLC)
Explore research and policy strategies to translate scientific knowledge on the convergence of the microbiome, prebiotics, probiotics, and host physiology into nutritional and therapeutic applications for inflammation, obesity, diabetes, gastrointestinal disease, and malnutrition.
Friday, May 17, 2013 | 8:00 AM - 4:30 PM
Speakers: Myron S. Cohen (UNC School of Medicine), Chris Collins (amfAR, The Foundation for AIDS Research), Michele R. Decker (Johns Hopkins Bloomberg School of Public Health), Tim Horn (Treatment Action Group), Rick King (IAVI), Luiz Loures (UNAIDS), Mary A. Marovich (NIAID), Nelson L. Michael (Walter Reed Army Institute of Research), Julio Montaner (BC Centre for Excellence in HIV / AIDS), John P. Moore (Weill Cornell Medical College), Robert R. Redfield (University of Maryland School of Medicine), Bill Snow (Global HIV Vaccine Enterprise), Magdalena Sobieszczyk (Columbia University Medical Center), Annie Sparrow (Mount Sinai Global Health), Daniel Tietz (ACRIA), Mitchell Warren (AVAC), Jane Waterman (IAVI)
The UNAIDS "three zeros" strategy provides a clear vision for future HIV / AIDS research and policy. This symposium tackles communication and collaboration, capacity-building for HIV prevention, care, and treatment, vaccine trials and a case study.
Monday, May 6, 2013 | 8:15 AM - 4:00 PM
Speakers: Kurt R. Brunden (University of Pennsylvania), Grant J. Carr (AMRI), Gabriela Chiosis (Memorial Sloan-Kettering Cancer Center), Jerold Chun (The Scripps Research Institute), Bonnie M. Davis (Synaptec), Chad Dickey (University of South Florida), Frank E. Koehn (Pfizer Global R&D), David J. Newman (National Cancer Institute, NIH), Salvatore Oddo (University of Texas Health Science Center, San Antonio), Giulio Maria Pasinetti (Mount Sinai School of Medicine)
Alzheimer's disease may benefit from the novel chemistries found in natural products. This conference explores drug discovery from natural products, including novel approaches and technologies, and promising Alzheimer's drug discovery programs.
Tuesday, April 23, 2013 | 12:00 PM - 4:00 PM
Speakers: Suzanne M. de la Monte (Brown University), William H. Frey II (Alzheimer's Research Center, Regions Hospital, St. Paul, MN), José A. Luchsinger (Columbia University Medical Center), Mark P. Mattson (National Institute on Aging, NIH), Ewan C. McNay (University at Albany, SUNY), Konrad Talbot (University of Pennsylvania)
Organizers: Mercedes Beyna (Pfizer Global Research and Development), Cathleen Gonzales (Pfizer Global Research and Development), Barbara Petrack (Drew University), Jennifer Henry (The New York Academy of Sciences)
Insulin resistance and dysregulated insulin signaling are observed in brains of Alzheimer's patients. Current diabetes drugs that improve cognition and brain insulin signaling in rodents are in clinical trials for mild cognitive impairment and AD.
Monday, March 25, 2013 | 12:00 PM - 4:00 PM
Organizers: Robert Martone (Covance Biomarker Center of Excellence), Harald Murck (Covance Neuroscience Medical and Scientific Services), Jennifer Henry (The New York Academy of Sciences)
Speakers: Ron Duman (Yale University), Guosong Liu (Tsinghua University, China), Jorge Quiroz (Roche), Simone Sartori (University of Innsbruck, Austria), Carlos Zarate (National Institute of Mental Health, NIH)
Major depression is a devastating illness; current therapies based upon monoamine neurotransmitters are beneficial for only one in ten patients. This program reviews a paradigm shift in treatment targeting the glutamatergic neurotransmitter system.
Organizers: Johanne Morne (New York State Department of Health AIDS Institute), Sonja Noring (New York State Department of Health AIDS Institute), Cheryl Smith (New York State Department of Health AIDS Institute), AIDS Institute Social Media Workgroup (New York State Department of Health AIDS Institute), Brooke Grindlinger (The New York Academy of Sciences), and Kerstin Hofmeyer (The New York Academy of Sciences)
This eBriefing looks at the impact of digital technologies on clinical care, especially for HIV and other sexually transmitted infections, exploring eHealth strategies for patient-centered care and clinical decision support.
Organizers: Robert Martone (Covance Biomarker Center of Excellence), Harald Murck (Covance Neuroscience Medical and Scientific Services), and Jennifer Henry (The New York Academy of Sciences)
Speakers: Ronald S. Duman (Yale University School of Medicine), Guosong Liu (Tsinghua University, China), Jorge Quiroz (Roche), Simone B. Sartori (University of Innsbruck, Austria), and Carlos A. Zarate (National Institute of Mental Health, NIH)
Major depression is a devastating illness; current therapies based on monoamine neurotransmitters are beneficial for only one in ten patients. This eBriefing reviews a paradigm shift in treatment that targets the glutamatergic neurotransmitter system.
Edited by George R. Uhl
(National Institutes of Health, Baltimore, Maryland)
The fifth installment of this Annals series presents scholarly reviews on clinical, molecular, pharmacologic, imaging, genetic, and therapeutic aspects of addiction.
Edited by Alvin C. Powers
(Vanderbilt University, Nashville, Tennessee) and Rexford S. Ahima
(University of Pennsylvania, Philadelphia, Pennsylvania)
In-depth review articles on timely topics in obesity and diabetes research.
Foods high in antioxidants are believed to fight oxidative stress. But what is oxidative stress? Two scientists from a recent NYAS conference break it down and discuss whether antioxidants have superpowers.
Delve into the world of prebiotic and probiotic science. We talk to three people in the field and learn why keeping the good microbes in our bodies happy means a lot for health.
Neuropsychologist Jeffrey Halperin is using behavioral therapy on preschoolers with attention deficit hyperactivity disorder (ADHD). He hopes to train their brains to develop in new ways and if effective, his therapies could offer permanent, drug-free treatment for the disorder.
Researchers at Harvard have discovered why the headaches of some migraine sufferers worsen when the person is exposed to light. Rami Burstein, the study's senior author, explains what's happening in the brain, and how they made the breakthrough.
Translational Medicine Initiative
The Translational Medicine Initiative represents a three-year partnership between the New York Academy of Sciences and the Josiah Macy, Jr. Foundation to support the translation of basic science research into clinical applications.
Learn more at www.nyas.org/TransMed.